JP5006802B2 - 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１ - Google Patents

上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１

Info

Publication number
JP5006802B2
JP5006802B2 JP2007556362A JP2007556362A JP5006802B2 JP 5006802 B2 JP5006802 B2 JP 5006802B2 JP 2007556362 A JP2007556362 A JP 2007556362A JP 2007556362 A JP2007556362 A JP 2007556362A JP 5006802 B2 JP5006802 B2 JP 5006802B2
Authority
JP
Japan
Prior art keywords
cancer
cyr61
antibody
level
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007556362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530582A (ja
JP2008530582A5 (https=
Inventor
マーシャ エー． モーゼス，
ボー チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2008530582A publication Critical patent/JP2008530582A/ja
Publication of JP2008530582A5 publication Critical patent/JP2008530582A5/ja
Application granted granted Critical
Publication of JP5006802B2 publication Critical patent/JP5006802B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2007556362A 2005-02-18 2006-02-17 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１ Expired - Fee Related JP5006802B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65411105P 2005-02-18 2005-02-18
US60/654,111 2005-02-18
PCT/US2006/005812 WO2006089212A2 (en) 2005-02-18 2006-02-17 Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin

Publications (3)

Publication Number Publication Date
JP2008530582A JP2008530582A (ja) 2008-08-07
JP2008530582A5 JP2008530582A5 (https=) 2009-04-16
JP5006802B2 true JP5006802B2 (ja) 2012-08-22

Family

ID=36917123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007556362A Expired - Fee Related JP5006802B2 (ja) 2005-02-18 2006-02-17 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１

Country Status (7)

Country Link
US (4) US7858324B2 (https=)
EP (1) EP1849002A4 (https=)
JP (1) JP5006802B2 (https=)
CN (1) CN101120252A (https=)
AU (1) AU2006214105A1 (https=)
CA (1) CA2598217A1 (https=)
WO (1) WO2006089212A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
CN101120252A (zh) * 2005-02-18 2008-02-06 儿童医疗中心有限公司 作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61
JP2009536313A (ja) 2006-01-11 2009-10-08 レインダンス テクノロジーズ， インコーポレイテッド ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
ATE540750T1 (de) 2006-05-11 2012-01-15 Raindance Technologies Inc Mikrofluidische vorrichtung und verfahren
EP3536396B1 (en) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
JP5144742B2 (ja) * 2007-03-29 2013-02-13 フジレビオ ダイアグノスティックス インコーポレイテッド 乳がんの評価のためのｈｅ４の使用
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP2315629B1 (en) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
CN101747435B (zh) * 2008-12-18 2013-06-19 上海市免疫学研究所 一种中和cyr61的单克隆抗体(杂交瘤)及其应用
EP3415235B1 (en) 2009-03-23 2025-11-12 Bio-Rad Laboratories, Inc. Manipulation of microfluidic droplets
EP2273272A1 (en) 2009-07-06 2011-01-12 Stichting Katholieke Universiteit Method for predicting the outcome of chemotherapy in ovarian cancer
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3859011A1 (en) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Methods for forming mixed droplets
EP3736281A1 (en) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3709018A1 (en) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Microfluidic apparatus for identifying components of a chemical reaction
US20140220018A1 (en) * 2011-06-16 2014-08-07 Giovanni M. Pitari Biomarkers for epithelial cancer diagnosis and treatment
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP3495817B1 (en) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molecular diagnostic screening assay
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
KR102155531B1 (ko) 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
EP3524693A1 (en) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digital analyte analysis
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN105396136B (zh) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）在治疗皮肤损伤及皮肤萎缩相关疾病中的应用
CN107422125A (zh) * 2016-05-23 2017-12-01 中国医学科学院肿瘤医院 与肌层浸润性膀胱癌相关的尿液蛋白质标志物
EP3364190A1 (en) 2017-02-20 2018-08-22 Panka Cancer Research AG Method of detecting cancer or cancer cells
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
CN108752454B (zh) * 2018-06-19 2021-07-20 中山大学孙逸仙纪念医院 一种人CYR61蛋白Ser188位点磷酸化抗原、抗体及其制备方法和应用
CN111426835A (zh) * 2019-01-10 2020-07-17 北京师范大学 肝转移癌相关的尿液蛋白标记物的筛选及其用途
CN113777315A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液泛素样蛋白isg15及其多肽片段在烧伤中的应用
CN112147337B (zh) * 2020-08-19 2024-05-28 德赛诊断系统(上海)有限公司 一种富含半胱氨酸蛋白61高敏化学发光检测试剂盒及其制备和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
WO2001098359A2 (en) * 2000-06-21 2001-12-27 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
EP1322778A4 (en) * 2000-09-29 2005-06-15 Wyeth Corp APPLICATION OF CYR61 IN THE TREATMENT AND DIAGNOSIS OF HUMAN UTERUS MYOMENIC
US20040086504A1 (en) * 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20030113816A1 (en) 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
JP2003177126A (ja) * 2001-12-13 2003-06-27 Kenichi Katsube Ｃｃｎファミリー蛋白質活性制御剤のスクリーニング方法
WO2003058201A2 (en) * 2001-12-31 2003-07-17 Quark Biotech, Inc. Methods for identifying marker genes for cancer
MXPA05010385A (es) * 2003-03-27 2006-03-08 Childrens Hosp Medical Center Metodo y estuche para detectar el inicio temprano de lesion celular tubular renal.
JP2004315480A (ja) * 2003-04-21 2004-11-11 Yoshiyuki Kakehi 前立腺疾患治療用医薬組成物
CN101120252A (zh) * 2005-02-18 2008-02-06 儿童医疗中心有限公司 作为生物标记物用于上皮来源的癌症的诊断和预后的cyr61

Also Published As

Publication number Publication date
CN101120252A (zh) 2008-02-06
JP2008530582A (ja) 2008-08-07
WO2006089212A2 (en) 2006-08-24
CA2598217A1 (en) 2006-08-24
US20110189700A1 (en) 2011-08-04
AU2006214105A1 (en) 2006-08-24
EP1849002A4 (en) 2008-08-20
US7858324B2 (en) 2010-12-28
US20190154693A1 (en) 2019-05-23
US20080286811A1 (en) 2008-11-20
US20170205419A1 (en) 2017-07-20
WO2006089212A3 (en) 2007-01-11
EP1849002A2 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
JP5006802B2 (ja) 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１
US20190361028A1 (en) Free ngal as a biomarker for cancer
US8685659B2 (en) Method for diagnosis and prognosis of epithelial cancers
US20100209944A1 (en) Adamts-7 as a biomarker for cancers of epithelial origin
JP4847873B2 (ja) 上皮起源の癌を診断および予後診断するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090212

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120329

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120517

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120525

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150601

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5006802

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees